ライフサイエンスコーパス: intravitreal

1 Patients either received intravitreal 0.5 mg ranibizumab monthly, monthly ranibiz

2 Patients were randomized 1:1 to intravitreal 2 mg aflibercept every 4 weeks (monthly) or

3 ment-naive patients were randomized 1:1:1 to intravitreal 6.0 mg faricimab, 1.5 mg faricimab, or 0.3

4 Therapeutic intravitreal administration of 19,20-DHDP not only suppr

5 Intravitreal administration of avacincaptad pegol 2 mg a

6 Evaluate the impact of intravitreal aflibercept (Eylea; Regeneron, Tarrytown, N

7 b (IVB), intravitreal ranibizumab (IVR), and intravitreal aflibercept (IVA) for the treatment of macu

8 To compare efficacy and safety of intravitreal aflibercept (IVA) injection with panretinal

9 ted macular degeneration (nAMD) treated with intravitreal aflibercept (IVT-AFL) injection.

10 Intravitreal aflibercept + anti-PDGFRbeta did not improv

11 Patients received intravitreal aflibercept 2 mg every 8 weeks for 52 weeks

12 istered suprachoroidally in conjunction with intravitreal aflibercept compared with aflibercept monot

13 istered suprachoroidally in conjunction with intravitreal aflibercept for treatment of DME provides s

14 degeneration (AMD) and response to as-needed intravitreal aflibercept injection (IAI) therapy for exu

15 Eyes received either intravitreal aflibercept injection 2 mg every 4 weeks (2

16 Intravitreal aflibercept injection resulted in significa

17 ata from VIEW 1 and 2 of 1804 eyes receiving intravitreal aflibercept injections (IAIs) 2 mg every 4

18 A 71 year old male who was receiving intravitreal aflibercept injections for neovascular age-

19 Intravitreal aflibercept injections resulted in a dramat

20 Intravitreal aflibercept maintains acceptable lifetime c

21 Participants received monthly intravitreal aflibercept or bevacizumab through month 6

22 Intravitreal aflibercept was associated with clinically

23 consistent with the known safety profile of intravitreal aflibercept.

24 ded the retina specialist's recommendations: intravitreal agent, interval between injections, number

25 tic confirmation or high index of suspicion, intravitreal amikacin is preferred.

26 Combination intravitreal and systemic antiviral therapy for ARN can

27 Determine the efficacy of combination intravitreal and systemic antiviral therapy for the trea

28 g resistant, and was treated with maribarir, intravitreal and systemic injections of foscarnet, and a

29 s combinations of corticosteroids (systemic, intravitreal, and topical), and 2 eyes underwent vitrect

30 including with anti-VEGF agents, to inhibit intravitreal angiogenesis and facilitate vascularization

31 ere randomized 1:2:2 to low-dose combination intravitreal anti-PDGFRbeta 1 mg and aflibercept 2 mg (L

32 rcept 2 mg (LD combo), high-dose combination intravitreal anti-PDGFRbeta 3 mg and aflibercept 2 mg (H

33 t neovascularization on presentation; (3) no intravitreal anti-vascular endothelial growth factor (an

34 ctors for nonadherence and nonpersistence to intravitreal anti-vascular endothelial growth factor (VE

35 Intravitreal anti-vascular endothelial growth factor (VE

36 Intravitreal anti-vascular endothelial growth factor (VE

37 Intravitreal anti-vascular endothelial growth factor (VE

38 e reactivation included observation (n = 1), intravitreal anti-vascular endothelial growth factor age

39 StudyPopulation: Eyes receiving intravitreal anti-vascular endothelial growth factor inj

40 efined as ophthalmologists performing either intravitreal anti-vascular endothelial growth factor inj

41 py and ultimately amenable to treatment with intravitreal anti-vascular endothelial growth factor inj

42 roidal rupture after ocular trauma receiving intravitreal anti-VEGF (vascular endothelial growth fact

43 Eyes with PDR that received only intravitreal anti-VEGF demonstrated worse anatomic and f

44 t follow-up have been reported on the use of intravitreal anti-VEGF for traumatic choroidal neovascul

45 Our results suggest intravitreal anti-VEGF injections are linked to higher r

46 rugs combined to cyclophotocoagulation and 7 intravitreal anti-VEGF injections for recurrent iris neo

47 tients with exudative AMD who were receiving intravitreal anti-VEGF injections from September 1, 2015

48 insufficient data to determine the impact of intravitreal anti-VEGF injections on glaucoma progressio

49 Subjects receiving intravitreal anti-VEGF injections outside of study proto

50 Of 204,986 intravitreal anti-VEGF injections performed, 60 cases (0

51 s in vascular congestion and exudation after intravitreal anti-VEGF injections.

52 Intravitreal anti-VEGF naive patients seen between 2010

53 ion, or major bleeding within 6 months after intravitreal anti-VEGF pharmacotherapy for the treatment

54 Eyes with nAMD receiving intravitreal anti-VEGF that were LTFU experience signifi

55 Intravitreal anti-VEGF therapy delayed but did not preve

56 n age of 29 years (SD 12.4; range 19-45) had intravitreal anti-VEGF therapy for traumatic CNV.

57 CT feature frequently seen in eyes receiving intravitreal anti-VEGF therapy for type 1 MNV due to AMD

58 Discounted cash flow analysis of intravitreal anti-VEGF treatment for nAMD resulted in a

59 Patients with eyes receiving either intravitreal anti-VEGF treatment or PRP with the next fo

60 Exclusion criteria were prior intravitreal anti-VEGF treatment, invasive ophthalmologi

61 13 365 received macular laser, 9219 received intravitreal anti-VEGF, and 764 received intravitreal co

62 iation with adverse reactions after standard intravitreal antibiotic administration.

63 ion cephalosporins, some providers alter the intravitreal antibiotic choice for endophthalmitis becau

64 Immediate intravitreal antibiotic delivery was a universal first-l

65 Exclusion criteria were intravitreal antibiotic injection and follow-up of less

66 linical management was defined as additional intravitreal antibiotic injections or pars plana vitrect

67 real antibiotics alone versus early PPV plus intravitreal antibiotics (29.5% [18 eyes] vs. 25.0% [44

68 s whether the eye was managed primarily with intravitreal antibiotics alone versus early PPV plus int

69 reful informed consent process when choosing intravitreal antibiotics for patients with specific anti

70 ent disease course and excellent response to intravitreal antibiotics is consistent with previous oph

71 All eyes received intravitreal antibiotics on the same day of diagnosis.

72 Same-day injection of intravitreal antibiotics was the universal first-line th

73 an initial pars plana vitrectomy (PPV) with intravitreal antibiotics, none of which required a secon

74 phthalmitis responded well to treatment with intravitreal antibiotics.

75 r, culture results may not influence initial intravitreal antimicrobial choice.

76 Initial management included intravitreal antimicrobials with aqueous tap in 46% of e

77 intraocular culture sample and injection of intravitreal antimicrobials.

78 Of those eyes, 93.3% were receiving intravitreal antivascular endothelial growth factor (VEG

79 nvolvement, despite combination systemic and intravitreal antiviral therapy; however, none of the 19

80 To evaluate the effectiveness of intravitreal bevacizumab (IVB) and intravitreal ranibizu

81 Medium- and long-term sequelae of intravitreal bevacizumab (IVB) for type 1 retinopathy of

82 sed to calculate comparative cost-utility of intravitreal bevacizumab (IVB), intravitreal ranibizumab

83 doption of OCT-guided therapy and the use of intravitreal bevacizumab by the global retinal community

84 raphy images were evaluated before and after intravitreal bevacizumab injection.

85 It included 503 eyes which received intravitreal bevacizumab over a period of 2 years withou

86 ranibizumab not yet commercially available, intravitreal bevacizumab rapidly became adopted worldwid

87 Treatment with intravitreal Bevacizumab resulted in unmasking of the pr

88 ihood of visual acuity improvement following intravitreal bevacizumab treatment compared with White a

89 general anesthesia and infants treated with intravitreal bevacizumab under local sedation using mult

90 Infants treated with intravitreal bevacizumab using bedside sedation returned

91 study was to compare the systemic safety of intravitreal bevacizumab, ranibizumab, and aflibercept i

92 pitalization after treatment initiation with intravitreal bevacizumab, ranibizumab, or aflibercept du

93 Eyes that received intravitreal bevacizumab, ranibizumab, or aflibercept fo

94 Exposures: Intravitreal bevacizumab.

95 c Studies (BPKLCOS) among patients receiving intravitreal bevacizumab.

96 such as Vitrasert(R) from Bausch & Lomb, an intravitreal biodegradable polymeric implant made from p

97 Of the 53 patients who received intravitreal ceftazidime, 46 (86.8%) had allergies to PC

98 treal vancomycin, and 81.5% (53/65) received intravitreal ceftazidime.

99 y may not be an absolute contraindication to intravitreal cephalosporin use.

100 stemic chemotherapy (53% vs. 64%, P = 0.29), intravitreal chemotherapy (59% vs. 28%, P = 0.005), and

101 Intravitreal co-injection of norrin with VEGF completely

102 tinal photocoagulation (PRP) associated with intravitreal conbercept injections versus PRP alone in t

103 ved intravitreal anti-VEGF, and 764 received intravitreal corticosteroid as initial treatment.

104 eated with macular laser photocoagulation or intravitreal corticosteroid.

105 Intravitreal delivery of antibody-based therapeutics has

106 stimulation of retinal astrocytic growth by intravitreal delivery of PDGF-A was sufficient to block

107 India to examine the safety of dexamethasone intravitreal (DEX) implant over 1 year in Indian patient

108 ors for the anterior chamber migration of an intravitreal dexamethasone implant (Ozurdex(R)).

109 The intravitreal dexamethasone implant (Ozurdex) is effectiv

110 A retrospective review of 640 consecutive intravitreal dexamethasone implant injections was conduc

111 The anterior chamber migration of an intravitreal dexamethasone implant is a serious complica

112 is study aimed to evaluate the effect of the intravitreal dexamethasone implant Ozurdex(R) in patient

113 c eyes who had DME, primary therapy with the intravitreal dexamethasone implant PRN (for 2 years) res

114 Intravitreal dexamethasone implant was noninferior to IT

115 intravitreal injection (e.g. Ozurdex(R), an intravitreal dexamethasone implant).

116 To identify different response patterns to intravitreal dexamethasone implants (IDI) in naive and p

117 Intravitreal dexamethasone reduced the requirement of en

118 qually (1:1:1) to receive a single bilateral intravitreal dose of ranibizumab 0.2 mg or ranibizumab 0

119 ATP5H) in primary RGCs and in vivo following intravitreal ET-1 injection in rats.

120 Strikingly, intravitreal griseofulvin decreased both pathological tu

121 erent alternatives, among them Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) has demonstrated t

122 oth the first and second episodes was recent intravitreal injection (50% and 58.3%, respectively) fol

123 ds are currently delivered inside the eye by intravitreal injection (e.g. Ozurdex(R), an intravitreal

124 Pain after an intravitreal injection (IVI) can last up to 7 days and n

125 Importantly, one intravitreal injection (IVI) of 25 pmol MTX increased el

126 In contrast, after 1 intravitreal injection (IVI) of antibiotics, the identif

127 ted macular degeneration (nAMD) treated with intravitreal injection (IVI) of brolucizumab.

128 The intravitreal injection (IVI) of pharmacologic agents is

129 A 100 uL intravitreal injection (IVI) of saline was given in one

130 ts when measured between 0 and 30 minutes of intravitreal injection and that the IOP elevation decrea

131 tion presented 4 weeks after his most recent intravitreal injection and was found to have endophthalm

132 Intravitreal injection can be given safely without pre-o

133 uce longer-term local drug administration by intravitreal injection compared to previously reported d

134 As in this case, post-intravitreal injection endophthalmitis may have a bacter

135 D that occurred within 90 days of a previous intravitreal injection for nAMD.

136 a combination of both, were administered by intravitreal injection immediately after laser injury.

137 luted when used as an antiseptic prior to an intravitreal injection in an attempt to decrease patient

138 Intravitreal injection is associated with rare but poten

139 Although RRD after intravitreal injection is rare, prior retinal surgery an

140 n of NIU, naive Lewis rats received a single intravitreal injection of AAV particles harboring codon-

141 xygen-induced retinopathy resulting from the intravitreal injection of adipose Myh11-derived mesenchy

142 Both intravitreal injection of aflibercept followed by PRP an

143 Patients who developed endophthalmitis after intravitreal injection of aflibercept, bevacizumab, or r

144 Intravitreal injection of anti-VEGF agents results in an

145 Following endophthalmitis from intravitreal injection of anti-VEGF agents, vitreous cul

146 Review of the literature indicates that intravitreal injection of anti-VEGF therapy is safe and

147 53) underwent initial bedside aspirate with intravitreal injection of antibiotics (tap-and-injection

148 then treated either with a vitreous tap and intravitreal injection of antibiotics or with pars plana

149 in the proportion of eyes requiring a second intravitreal injection of antibiotics whether the eye wa

150 In summary, the combination of intravitreal injection of conbercept and PRP can signifi

151 ents which responded well to intravenous and intravitreal injection of corticosteroids.

152 the patient was treated with intravenous and intravitreal injection of corticosteroids.

153 Ocular toxicity studies revealed that intravitreal injection of griseofulvin in adult mice doe

154 Eyes were randomized to either a single intravitreal injection of ocriplasmin or placebo treatme

155 Patients received a single 0.125 mg intravitreal injection of ocriplasmin.

156 nths in comparison to standard therapy, i.e. intravitreal injection of ranibizumab alone.

157 A single intravitreal injection of Ro5-3335 significantly decreas

158 An intravitreal injection of the FECH inhibitor N-methyl pr

159 udy evaluated the efficacy and safety of the intravitreal injection of ziv-aflibercept in patients wi

160 ioned at 20 cm in a simulated position of an intravitreal injection procedure.

161 patient refused oral corticosteroids and any intravitreal injection therapies.

162 .04 +/- 1.89 mum rendering them suitable for intravitreal injection using conventional 25G-32G needle

163 The intravitreal injection was given by a single surgeon.

164 mean (SEM) VAS pain scores immediately after intravitreal injection were 2.3 +/- 0.4 for patients rec

165 Additional risk factors for RRD other than intravitreal injection were present in 5 of 13 eyes (38%

166 reported cases of RRD in patients with prior intravitreal injection who underwent subsequent surgical

167 ionship between IOP increase and the type of intravitreal injection, number of intravitreal injection

168 model as well as local ocular suppression in intravitreal injection-induced AP activation model in mi

169 re identified to have RRD within 3 months of intravitreal injection.

170 factors for RRD may predispose to RRD after intravitreal injection.

171 gain with less incidence of recurrence than intravitreal injection.

172 treal injections (0.0084%) within 90 days of intravitreal injection.

173 owing increase in intraocular pressure by an intravitreal injection.

174 the DVC and a poor anatomical response after intravitreal injection.

175 IOP were detected in either group after the intravitreal injection.

176 ficantly associated with cyst response after intravitreal injection.

177 g through an undilated pupil followed by the intravitreal injection.

178 of first injection and frequency interval of intravitreal injection.

179 al allergic reactions or complications after intravitreal injection.

180 but potentially devastating complication of intravitreal injection.

181 atients diagnosed with DME who had undergone intravitreal injection.

182 ated RRDs, giving a rate of 1 RRD per 11 941 intravitreal injections (0.0084%) within 90 days of intr

183 r injection, giving a rate of 1 RRD per 7532 intravitreal injections (0.013%) and 1 RRD per 530 patie

184 s listed more ocular-specific routes such as intravitreal injections (2), retrobulbar injections (2),

185 ts independently perform procedures, such as intravitreal injections (23.1%) and minor lid procedures

186 es), whereas the remaining were secondary to intravitreal injections (35 eyes [14.8%]), PPV (29 eyes

187 Predictors of VA gain included number of intravitreal injections (AMD and PCV adjusted odds ratio

188 AIDs) for the reduction of ocular pain after intravitreal injections (IVIs) has been explored.

189 ely used as an ocular surface antiseptic for intravitreal injections (IVIs).

190 e material available to the public regarding intravitreal injections (IVIs).

191 rofile during treatment, number of antiviral intravitreal injections (IVT), retinal detachment rate,

192 Of 483,622 intravitreal injections administered, 168 out of 453,460

193 educed bacterial dispersion during simulated intravitreal injections and had no difference in bacteri

194 rior anti-vascular endothelial growth factor intravitreal injections and were responsive to treatment

195 Intravitreal injections are a mandatory treatment for ma

196 Intravitreal injections are the most common treatment mo

197 assessment of the Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secon

198 the rate of RNFL thinning in eyes receiving intravitreal injections did not significantly differ fro

199 al superiority of 1-time therapy to repeated intravitreal injections due to reduction in adverse even

200 An exact total of 203 000 intravitreal injections for nAMD were administered.

201 Since 2015 our treatment scheme for intravitreal injections has been switched from PRN to TE

202 A total of 180 671 intravitreal injections in 12 718 unique patients were i

203 Intravitreal injections in eyes receiving multiple regul

204 0-day rate of RRD in nAMD patients receiving intravitreal injections is low.

205 ism underlying IOP elevation associated with intravitreal injections is unknown.

206 The cumulative number of intravitreal injections may be an independent risk facto

207 n monthly or every other month (EOM) or sham intravitreal injections monthly or EOM for 12 months wit

208 diabetic macular edema (DME) received three intravitreal injections of 0.5 mg ranibizumab during the

209 igned randomly in a 2:2:1:1 ratio to receive intravitreal injections of 15 mg pegcetacoplan monthly o

210 NCT03140969 ) with intravitreal injections of an antisense oligonucleotide

211 Three patients were treated with 2.3 +/- 0.6 intravitreal injections of anti-vascular endothelial gro

212 Neovascular AMD patients receiving intravitreal injections of anti-VEGF during the study pe

213 at these patients are less likely to receive intravitreal injections of anti-VEGF medication, laser t

214 ur study was to investigate whether repeated intravitreal injections of anti-VEGF would increase the

215 Comparing the efficacy of intravitreal injections of bevacizumab to ranibizumab in

216 der with diabetic macular edema who received intravitreal injections of bevacizumab.

217 ocular hypertension (OHT), comparing single intravitreal injections of microspheres of DMQ-MSs to th

218 tients were randomized 1:1 to receive either intravitreal injections of ranibizumab 0.5 mg or afliber

219 Intravitreal injections of spironolactone-loaded microsp

220 Intravitreal injections of triamcinolone obtained from a

221 DME is commonly treated with intravitreal injections of vascular endothelial growth f

222 face masks were worn by the physician during intravitreal injections or "No Talking" group if no face

223 g-term follow-up received significantly more intravitreal injections per year than eyes with inconsis

224 ce visits and received a mean of 5.8 +/- 2.5 intravitreal injections per year.

225 ients undergoing OCT-guided retreatment with intravitreal injections resulted in decreased exposure t

226 (RNFL) thinning is faster in eyes receiving intravitreal injections than in fellow uninjected eyes a

227 ces in angle width associated with number of intravitreal injections that might explain this phenomen

228 g glaucoma in both eyes receiving unilateral intravitreal injections were identified.

229 ess, treatment interval, and total number of intravitreal injections were secondary outcomes.

230 To mask both groups, sham suprachoroidal and intravitreal injections were utilized.

231 iseases usually need chronic treatment using intravitreal injections with anti-VEGF agents.

232 Patients were treated with intravitreal injections with bevacizumab; ranibizumab; o

233 r NPDR, PDR, or DME or a procedural code for intravitreal injections, pars plana vitrectomy (PPV) or

234 he type of intravitreal injection, number of intravitreal injections, preexisting glaucoma, and globe

235 Current therapies require repeated intravitreal injections, which are painful and can cause

236 group included 147 fellow eyes with no prior intravitreal injections.

237 outine VA assessment, DFEs, OCT imaging, and intravitreal injections.

238 program and for patients receiving anti-VEGF intravitreal injections.

239 but a no-talking policy was observed during intravitreal injections.

240 inclusion criteria, receiving 26.4 +/- 15.9 intravitreal injections.

241 almitis is rare and seen most commonly after intravitreal injections.

242 h endophthalmitis after cataract surgery and intravitreal injections.

243 ng optical coherence tomography (OCT)-guided intravitreal injections.

244 antibioprophylaxis remains controversial in intravitreal injections.

245 ographics, visual acuity (VA), and number of intravitreal injections.

246 with patient face mask use during simulated intravitreal injections.

247 rent nAMD standard of care dictates frequent intravitreal (IVT) anti-vascular endothelial growth fact

248 on-controlled clinical trials that evaluated intravitreal lampalizumab in GA.

249 Intravitreal MBV injections attenuated IOP-induced RGC a

250 ent initiated with combined intracameral and intravitreal melphalan injections given according to the

251 with only a small number of intracameral and intravitreal melphalan injections.

252 d (pulsatile vs. continuous), or concomitant intravitreal melphalan use.

253 xt of metastatic cutaneous melanoma includes intravitreal metastasis, and this seems to be particular

254 In vivo a single intravitreal microinjection of mAbFzd7 or CRD significan

255 Intravitreal NVAMD bevacizumab, ranibizumab and afliberc

256 y, we enrolled sixteen VMT eyes treated with intravitreal ocriplasmin injection.

257 A phase 1 trial assessed the safety of intravitreal OPT-302 as monotherapy or combined with ran

258 Intravitreal OPT-302 inhibition of VEGF-C and -D was wel

259 Intravitreal OPT-302 with or without ranibizumab was wel

260 h potent corticosteroids (topical, subtenon, intravitreal, or systemic) is recommended, which may be

261 es were laser-naive and had not received any intravitreal pharmacotherapy within 6 months of UWFA.

262 veness of intravitreal bevacizumab (IVB) and intravitreal ranibizumab (IVR) in actual practice for tr

263 t-utility of intravitreal bevacizumab (IVB), intravitreal ranibizumab (IVR), and intravitreal afliber

264 Patients received intravitreal ranibizumab 0.5 mg injections in adherence

265 ml, PDS 40-mg/ml, PDS 100-mg/ml, and monthly intravitreal ranibizumab 0.5-mg arms, respectively.

266 ml, PDS 40-mg/ml, PDS 100-mg/ml, and monthly intravitreal ranibizumab 0.5-mg arms, respectively.

267 arable between the PDS 100-mg/ml and monthly intravitreal ranibizumab 0.5-mg arms, with a lower total

268 was similar in the PDS 100-mg/ml and monthly intravitreal ranibizumab 0.5-mg arms.

269 nd anatomic outcomes comparable with monthly intravitreal ranibizumab 0.5-mg injections but with a re

270 mg/ml, and 100-mg/ml formulations or monthly intravitreal ranibizumab 0.5-mg injections.

271 ab 10 mg/ml, 40 mg/ml, 100 mg/ml, or monthly intravitreal ranibizumab 0.5-mg injections.

272 S 10-mg/ml, 40-mg/ml, 100-mg/ml, and monthly intravitreal ranibizumab 0.5-mg treatment arms, respecti

273 was similar in the PDS 100-mg/ml and monthly intravitreal ranibizumab 0.5-mg treatment arms.

274 nts with nAMD were randomized 1:1 to receive intravitreal ranibizumab at a dose of 0.5 mg in either a

275 We evaluated the efficacy and safety of intravitreal ranibizumab compared with laser therapy in

276 ion standard photodynamic therapy (PDT) with intravitreal ranibizumab in the treatment of polypoidal

277 ts were randomly assigned to receive monthly intravitreal ranibizumab injections either until macular

278 In eyes with DME, monthly intravitreal ranibizumab injections resulted in signific

279 In silico modeling predicted prolonged intravitreal retention of an antibody-based therapeutic

280 st-procedural endophthalmitis as the role of intravitreal steroids in treatment algorithms of endopht

281 Adjunctive therapies in the form of intravitreal steroids, systemic steroids, and systemic a

282 e randomized 1:1 to surgical implantation of intravitreal sustained delivery of human CNTF versus a s

283 n optic neuropathy, and 45 were treated with intravitreal therapy (triamcinolone, bevacizumab, and/or

284 Patients treated with intravitreal therapy for radiation optic neuropathy show

285 ion of the optic disc before irradiation and intravitreal therapy to treat cystoid macular edema not

286 mbined intracameral (total dose 8.1 mug) and intravitreal (total dose 70 mug) melphalan injections gi

287 focal area on the surface of the eye before intravitreal treatment (IVT).

288 ) or retinal vein occlusion (RVO), receiving intravitreal treatment at the retinal clinic, Zealand Un

289 Intravitreal treatment costs in the GA:CNV group were ex

290 sk of having IOP >=24 mmHg was higher in the intravitreal treatment groups compared with the periocul

291 was no significant difference between the 2 intravitreal treatment groups.

292 Participants received three intravitreal treatments of OPT-302 once every 4 weeks ei

293 is risk did not differ significantly between intravitreal treatments.

294 Intravitreal triamcinolone acetonide (PropBL ITA/PropBL

295 Intravitreal triamcinolone acetonide and the IDI were su

296 izumab, and this observation soon led to the intravitreal use of bevacizumab in 2005.

297 acteria were sensitive to the combination of intravitreal vancomycin and ceftazidime.

298 treatments of bacterial endophthalmitis are intravitreal vancomycin and ceftazidime.

299 ith a documented vancomycin allergy received intravitreal vancomycin without complication.

300 All patients (65/65) received intravitreal vancomycin, and 81.5% (53/65) received intr